Trial Profile
Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Jun 2020 Results evaluating the impact of the oral microbiome on risk factors and/or outcome of patients with multiple myeloma, presented at the 25th Congress of the European Haematology Association
- 27 Sep 2019 Results published in the British Journal of Cancer
- 05 Jul 2019 This trial has been completed in Germany(end date: 2019-03-28), according to European Clinical Trials Database.